Unveiling Roivant Sciences (ROIV) Stocks

By Blake Campbell • Wednesday, September 03 10:18 • Permanent Link

Join us for a quick overview of Roivant Sciences, a Pharmaceutical company whose shares moved 1.2% today. Here are some facts about the stock that should help you see the bigger picture:

Roivant Sciences has moved 5.4% over the last year, and the S&P 500 logged a change of 16.2%
ROIV has an average analyst rating of buy and is -26.26% away from its mean target price of $17.0 per share
Its trailing earnings per share (EPS) is $-1.09
Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -11.5 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $-1.19 and its forward P/E ratio is -10.5
The company has a Price to Book (P/B) ratio of 1.97 in contrast to the S&P 500's average ratio of 4.74
Roivant Sciences is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $-278103136, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.